Antiretroviral Therapy (Art) — Combination Regimens
Noted Infectious diseaseAuthority RequiredFirst-line line
Initial and continuing treatment of HIV infection in antiretroviral-naïve patients, with removal of the CD4+ count restriction (previously <500 cells/mm³) to allow initiation at any CD4+ count.
1
Submissions
2013–13
On the record
—
ICER range
Not modelled
Cost basis
Access path
- Nov 2013Noted
vs deferred therapy (no treatment)
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
This is a policy/restriction removal submission with no economic model presented. No ICER was calculated or discussed.
Decision context
PopulationAsymptomatic, antiretroviral-naïve HIV-positive patients with CD4+ cell count >500 cells/mm³ at diagnosis.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2013 | Noted | deferred therapy (no treatment) | — | RCT · Surrogate |
Similar precedents
Tenofovir Disoproxil Fumarate With Emtricitabine And Rilpivirine Hydrochloride70%Darunavir With Cobicistat With Emtricitabine And Tenofovir Alafenamide69%Abacavir Sulfate With Lamivudine68%Tenofovir Alafenamide, Emtricitabine, And Rilpivirine68%Emtricitabine + Tenofovir Alafenamide68%Dolutegravir68%Raltegravir67%Tenofovir Alafenamide / Emtricitabine / Rilpivirine67%